| 9M24 | 9M23 | 2023 | 2022 |
|---|
| Revenues | 909.31 | 991.23 | 1,317.67 | 1,510.55 |
| Expenses | 888.26 | 962.25 | 1,272.94 | 1,425.32 |
| Net Profit (Loss) | -6.03 | 6.67 | 13.43 | 53.04 |
| Assets | 1,367.53 | 1,440.61 | 1,368.33 | 1,544.11 |
| Liabilities | 848.94 | 926.60 | 843.71 | 1,037.70 |
| Shareholders' Equity | 518.59 | 514.01 | 524.62 | 506.42 |
| Operating | 157.93 | 1.55 | 39.32 | 223.60 |
| Investing | -24.86 | -9.93 | -27.50 | -58.68 |
| Financing | -77.93 | -88.40 | -115.50 | -155.01 |
| EPS (Baht) | 0.00 | 0.00 | 0.01 | |
| GP Margin (%) | 34.03 | 34.49 | 33.60 | 33.22 |
| NP Margin (%) | -0.66 | 0.67 | 1.02 | 3.51 |
| D/E Ratio (x) | 1.64 | 1.80 | 1.61 | 2.05 |
| ROE (%) | 0.14 | 4.92 | 2.60 | 11.80 |
| ROA (%) | 2.62 | 3.79 | 3.07 | 5.29 |
The Company focuses to operate in Medical Device business by Increasing product lines with both new products and expanding existing ones. The Company also emphasizes to achieve substantial growth in the medical device business, particularly in Medical Software and Hospital Infrastructure including specialized medical centers together with Collaborating on telemedicine systems and Electronic Medical Record (EMR) systems, Participating in various Turnkey projects and engage in the sales of innovative products, including ozone generator-based decomposing sterilizers, neutralizers, dental unit machines, and more. The Company's plan to increase revenue involves focusing on the sale of software that operates with the Company's medical devices, both developed or produced internally and imported from abroad. The strategy includes evolving into AI-based systems, a market with potential for future growth.
- The runner-up award in the AKA group (consisting of ASEAN countries, South Korea, and Australia) for being a representative distributor with excellent performance in terms of sales volume, orders, and overall operation as a GE Healthcare distributor.
- Sales Excellence Aword 2023, Class C, as a DIRUI distributor.
On January 22, 2024, The Company had entering into a partnership with Worm Link Co., Ltd., a leading manufacturer and developer of video recording, Image Capturing and reporting systems of endoscopic surgeries “Endolink”. The Company was appointed as the authorized distributor and service provider of Endolink products in Thailand. Endolink is a technologically advanced product designed to support healthcare and enhance operational efficiency in endoscopic procedures, aligning with the demands of the digital era, both present and future.
The total revenue for Q3/2024 of the Company and its subsidiaries amounted to THB 399 million, an increase of THB 60 million or a growth of 18 percent compared to the same period last year. As a result, the Group reported a profit of THB 37 million in Q3/2024, an increase of 179% compared to the same period last year.
For the 9-month period of 2024, the Group of Companies reported total revenue of THB 897 million, a decrease of THB 93 million or 9 percent compared to the same period last year. This resulted in a net loss of THB 6 million, representing a decrease of 190 percent from the prior year, due to underperformance in the last two quarters of 2024. This was primarily due to budget constraints and intense competition in the medical market.
However, the performance in Q3/2024 showed growth compared to the previous two quarters, as Q3 marks the close of the fiscal year for the government sector, during which customers typically accelerate contract signings and the delivery of goods to be completed by the end of September 2024.
- November 2022, EFORL signed a distributor agreement with Advanced Sterilization Products (Thailand) Limited appointing EFORL as a distributor for STERRAD low-temperature sterilization products using innovation in hydrogen peroxide gas plasma (HPGP) sterilization technology which helps enhance the safety of medical instruments, patients, sterile processing staff, and environment, and trusted by Healthcare institutions in Thailand and around the world.
- March 2023, EFORL signed a distributor agreement with Kazem Machinery & Tool Co., Ltd. appointing EFORL as the sole distributor of Air Purifier Machines in Thailand and overseas.
- June 2023, EFORL changed its paid-up capital from THB 2,998,398,735, representing a total of 3,998,477,193 ordinary shares at a par value of THB 0.75 per share. This change was due to the exercise of warrants (EFORL-W5) amounting to 409,208 units and warrants (EFORL-W6) amounting to 203,005 units, totaling 612,213 units converted into common shares.
- January 2024, EFORL had entering into a partnership with Worm Link Co., Ltd., a leading manufacturer and developer of video recording, Image Capturing and reporting systems of endoscopic surgeries “Endolink”. The Company was appointed as the authorized distributor and service provider of Endolink products in Thailand. Endolink is a technologically advanced product designed to support healthcare and enhance operational efficiency in endoscopic procedures, aligning with the demands of the digital era, both present and future.
The Company is exposed to exchange rate fluctuations risks as it
imports products from overseas. However, the Company has
protected risk from the fluctuation in exchange rate by making
forward contract and call option (if any) together with the
negotiation with the suppliers to make orders in Thai Baht through
the representation of suppliers in Thailand.
| as of 30/09/24 | EFORL | CONSUMP | mai |
|---|---|---|---|
| P/E (X) | - | 50.33 | 38.03 |
| P/BV (X) | 1.08 | 1.47 | 1.79 |
| Dividend yield (%) | - | 1.37 | 2.10 |
| 30/09/24 | 28/12/23 | 30/12/22 | |
|---|---|---|---|
| Market Cap (MB) | 519.80 | 999.62 | 1,359.27 |
| Price (B/Share) | 0.13 | 0.25 | 0.34 |
| P/E (X) | - | 40.56 | 19.68 |
| P/BV (X) | 1.08 | 1.94 | 2.78 |
